You are here:

Archived: argatroban (Exembol)

Advice

following a full submission:

argatroban (Exembol®) is not recommended for use within NHS Scotland.

Indication under review: anticoagulation in adult patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic therapy. 

Argatroban produces anticoagulant effects in adults with heparin-induced thrombocytopenia type II and there is limited evidence that it may be associated with a reduction in thrombosis, and deaths due to thrombosis. The submitting company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.

The licence holder has indicated their intention to resubmit.

Drug Details

Drug Name: argatroban (Exembol)
SMC Drug ID: 812/12
Manufacturer: Mitsubishi Pharma Europe Ltd
Indication: Anticoagulation in adult patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic therapy.
BNF Category:
Sub Category: 2.8 Anticoagulants and protamine
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 12 November 2012

Current Advice

Resubmission 12 August 2013

Back